<DOC>
<DOCNO>EP-0629211</DOCNO> 
<TEXT>
<INVENTION-TITLE>
4-OXO-2-THIOXOIMIDAZOLIDINE DERIVATES AS INHIBITORS OF BLOOD PLATELET AGGREGATION
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P4300	C07K5072	C07D23300	A61K3800	C07K5027	C07K5097	C07K500	C07K110	C07D23354	A61P4300	A61K3800	C07K5023	A61P3500	A61K314164	A61P702	A61K314164	C07K5117	A61P3500	A61P700	C07K100	C07D23386	C07K503	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07K	C07D	A61K	C07K	C07K	C07K	C07K	C07D	A61P	A61K	C07K	A61P	A61K	A61P	A61K	C07K	A61P	A61P	C07K	C07D	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P43	C07K5	C07D233	A61K38	C07K5	C07K5	C07K5	C07K1	C07D233	A61P43	A61K38	C07K5	A61P35	A61K31	A61P7	A61K31	C07K5	A61P35	A61P7	C07K1	C07D233	C07K5	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
HOECHST AG
</APPLICANT-NAME>
<APPLICANT-NAME>
HOECHST AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
JABLONKA BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
JUST MELITTA
</INVENTOR-NAME>
<INVENTOR-NAME>
KNOLLE JOCHEN
</INVENTOR-NAME>
<INVENTOR-NAME>
KOENIG WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
ZOLLER GERHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
JABLONKA, BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
JUST, MELITTA
</INVENTOR-NAME>
<INVENTOR-NAME>
KNOLLE, JOCHEN
</INVENTOR-NAME>
<INVENTOR-NAME>
KOENIG, WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
ZOLLER, GERHARD
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of the general formula I


in which

Y denotes -(CH
2
)
m
-CO-, where m stands for 1 or 2, or

R
1
 denotes - (CH
2
)
n
-NH-X, where n stands for a whole number
from 1 to 6, -(CH
2
)
p
-C
6
H
4
-NH-X, -(CH
2
)
p
-C
6
H
4
-C(=NH)-NH
2
 or
-(CH
2
)
p
-C
6
H
4
-CH
2
-NH-X, where p in each case stands for 1 or
2,

where, however  CH-R
1

can also be replaced by  C=CH-C
6
H
4
-X
1
;
X
1
 denotes -NHX, -CH
2
NHX or -C(=NH)-NH
2
;
X denotes hydrogen, (C
1
-C
6
)-alkyl or a radical of the
formula II



where R' and R", independently of each other, stand for
hydrogen or (C
1
-C
6
)-alkyl;
R
2
 denotes hydrogen or (C
1
-C
6
)-alkyl;
R
3
 denotes hydrogen or phenyl;
R
4
 denotes hydrogen or -CO-NH-R
5
, where -NH-R
5
 stands for
an α-amino acid residue or its ω-amino-(C
2
-C
8
)-alkylamide;
 
as well as their physiologically tolerated salts.
Compounds according to Claim 1, characterised in
that in the general formula I


R
1
 denotes -CH
2
-C
6
H
4
-NH-C(=NH)-NH
2
; -CH
2
-C
6
H
4
-C(=NH)-NH
2
 or
-CH
2
-C
6
H
4
-CH
2
-NH
2
;
R
2
 denotes hydrogen or methyl; and
R
3
 denotes hydrogen.
Compounds according to Claim 1 and/or 2,
characterised in that amino acid residues standing for

-NH-R
5
 are the valine residue, the phenylalanine residue
or the phenylglycine residue.
Compounds according to one or more of Claims 1 to 3,
characterised in that the ω-amino-(C
2
-C
8
)-alkylamide is
the 4-aminobutylamide.
Process for preparing compounds of Claims 1 to 4,
characterised in that a fragment condensation of a

compound of the general formula III


with a compound of the general formula IV


where the radicals R
1
 to R
4
 and Y are defined as indicated
in Claim 1, is carried out.
Compound of the general formula I according to one
or more of Claims 1 to 4 for use as an inhibitor of

platelet aggregation, of the metastasis of carcinoma
cells and of the binding of osteoclasts to the bone

surfaces.
Pharmaceutical product, characterized in that it
comprises one or more compounds of the general formula I

of Claims 1 to 4 or a physiologically tolerated salt
thereof as active substance together with pharmaceutically 

acceptable excipients and additives and
optionally one or more other pharmacological active

substances in addition.
Process for the preparation of a pharmaceutical
product comprising one or more compounds of the general

formula I of Claims 1 to 4 or a physiologically tolerated
salt thereof, characterized in that the latter is/are

brought into a suitable administration form together with
pharmaceutically acceptable excipients and additives and

optionally one or more other pharmacological active
substances in addition.
</CLAIMS>
</TEXT>
</DOC>
